BIOSCEPTRE
Biosceptre has identified a cancer target, nf-P2X7, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed to this target have the potential to treat all of these cancers. The Company is conducting multiple clinical trials to generate data that will underpin the potential of the technology. Concurrently Biosceptre is developing diagnostics that can detect and monitor cancer.
BIOSCEPTRE
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2000-01-01
Address:
Babraham, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.biosceptre.com
Total Employee:
11+
Status:
Active
Contact:
61 2 9889 1202
Total Funding:
16.14 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Genomed
Genomed markets protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Current Advisors List
Board_member
Current Employees Featured
Paul de Souza Chief Medical Officer @ Biosceptre
Chief Medical Officer
Patrick Schlegel Chief Medical Officer @ Biosceptre
Chief Medical Officer
Braden Roberts Chief Business Officer @ Biosceptre
Chief Business Officer
2019-10-01
Eddie Low Chief Financial Officer @ Biosceptre
Chief Financial Officer
Gavin Currie Chief Executive Officer @ Biosceptre
Chief Executive Officer
2012-10-01
Gary Faull Chief Financial Officer @ Biosceptre
Chief Financial Officer
2015-02-01
Founder
Investors List
Tuspark Science and Technology Service Group
Tuspark Science and Technology Service Group investment in Series A - Biosceptre
Bluesky Partnership II L.P
Bluesky Partnership II L.P investment in Series A - Biosceptre
Ian Valentine
Ian Valentine investment in Seed Round - Biosceptre
Official Site Inspections
http://www.biosceptre.com Semrush global rank: 9.39 M Semrush visits lastest month: 165
- Host name: syn01ee.syd5.hostyourservices.net
- IP address: 43.250.142.66
- Location: Australia
- Latitude: -33.494
- Longitude: 143.2104
- Timezone: Australia/Sydney
More informations about "Biosceptre"
Biosceptre – Promise beyond cancer
A Promise Beyond Cancer Envisioning the future of targeted therapeutics Biosceptre is driving innovation to bring new and progressive therapies to a wide range of cancer patients. Our …See details»
About - Biosceptre
ABOUT US Biosceptre is a biopharmaceutical company focused on the development of our BRiDGECAR™ system, which combines our nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy …See details»
Team – Biosceptre
Brad has been COD of Biosceptre since 2020, having joined Biosceptre as a Senior Manager (Legal and Compliance) in May 2013. With over 10 years’ experience in legal and compliance …See details»
Biosceptre - Crunchbase Company Profile & Funding
Biosceptre is driving innovation to bring new and progressive therapies to a wide range of cancer patients. Our focus is a multiple-targeted universal CAR T …See details»
Biosceptre 2025 Company Profile: Valuation, Funding …
Biosceptre General Information Description. Developer of chimeric antigen receptor T-cell therapy and antibody-based immune therapeutics designed to …See details»
Biosceptre - Funding, Financials, Valuation & Investors - Crunchbase
Biosceptre has identified a cancer target, nf-P2X7, present in many cancer types, and importantly not found in healthy tissue. New. Resources. Advanced Search. ... How much funding has this …See details»
Biosceptre - VentureRadar
" Biosceptre is a UK headquartered biotech developing next-generation cancer therapeutics utilising its proprietary target, nfP2X7.Biosceptre has multiple clinical programs designed to …See details»
Biosceptre Company Profile - Office Locations, Competitors ... - Craft
Biosceptre is a biopharmaceutical company developing targeted therapeutics and immune-oncology products against non-functional P2X7, a cancer target that is present on the majority …See details»
Biosceptre - Overview, News & Similar companies | ZoomInfo.com
Aug 21, 2018 Who is Biosceptre. Biosceptre is a privately held biopharmaceutical company focussed on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology therapeutic …See details»
Biosceptre - Contacts, Employees, Board Members, Advisors
Biosceptre has identified a cancer target, nf-P2X7, present in many cancer types, and importantly not found in healthy tissue. ... Experience the new Crunchbase, powered by AI . Experience …See details»
Biosceptre Company Information - Funding, Investors, and More
Biosceptre is a Cambridge, Cambridgeshire-based company developing diagnostic tools and biomarkers. Seedtable Score 76 Startups. 3. Funding Rounds. $13.2m. Money raised. About; …See details»
Investors - Biosceptre
INVESTORS Visionary pioneers, Biosceptre’s researchers are leading the way with the development of our multi-targeted BRiDGECAR™ system, including our nfP2X7-targeted …See details»
Biosceptre - FS Ventures
Biosceptre was founded in 2003, on science from the University of Sydney, Australia. With a UK headquartered Oncology Biotech with staff in Cambridge UK and Sydney Australia. Biosceptre …See details»
Biosceptre (Aust) Pty Ltd. (Biosceptre (Aust) Pty Ltd.) - 药物管线_专 …
The World Health Organization reports there were 14.1 million new cancer cases and 8.2 million cancer deaths in 2012 demonstrating significant unmet medical needs exist.Modifications to …See details»
Biosceptre | The Coco Group
Biosceptre is a UK based biotech R&D business investigating and exploiting a promising new target for the treatment of cancer – nfP2X7. nfP2X7 is a highly specific cancer target. Its non …See details»
Biosceptre - MTPConnect
Biosceptre is headquartered in the UK and has research underway in both Sydney and Cambridge, UK. Our pioneering team discovered the oncology target nfP2X7 – which is shown …See details»
Pipeline – Biosceptre
Pipeline Biosceptre 2024-03-28T16:46:12+11:00. PIPELINE. We know that our ground-breaking treatments have the potential to treat a range of malignancies and make a drastic difference to …See details»
Biosceptre - Updates, News, Events, Signals & Triggers - Crunchbase
Biosceptre has identified a cancer target, nf-P2X7, present in many cancer types, and importantly not found in healthy tissue.See details»
What is Biosceptre? Company Culture, Mission, Values
Biosceptre. Is this your company? This employer has not claimed their Employer Profile and is missing out on connecting with our community. Connect with our community. Claim your Free …See details»
Innovation - Biosceptre
INNOVATION Inspired and ambitious, our researchers are pioneers in cancer therapeutic development – focussed on developing our BRiDGECAR™ system, which combines our …See details»